Factors influencing hepatitis C cure in the era of direct-acting antivirals.

Factores que influyen en la curación de la hepatitis C en la era de los antivirales de acción directa.
Adherence Adherencia Chronic hepatitis C Cirrhosis Cirrosis Factores pronósticos Genotipo Genotype Hepatitis crónica C Prognostic factors Respuesta viral Sustained viral response sostenida

Journal

Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671

Informations de publication

Date de publication:
Sep 2019
Historique:
pubmed: 21 6 2020
medline: 10 7 2020
entrez: 21 6 2020
Statut: ppublish

Résumé

Direct-acting antiviral agents are highly potent drugs with a strong genetic barrier. Consequently, the factors influencing hepatitis C cure have been reduced and have progressively lost importance. Host factors, such as the presence of cirrhosis, race, and treatment adherence, influence sustained viral response. Adherence, together with treatment errors and drug interactions, are also important, especially in older patients. Viral factors, such as viral load, genotype, and the presence of baseline resistances affect the response rate but their influence can be minimised by using pan-genotypic regimens. Treatment simplification and the high efficacy of new antiviral treatments will allow treatment universalisation and will hopefully enable elimination of the infection in the next few decades. Supplement information: This article is part of a supplement entitled "The value of simplicity in hepatitis C treatment", which is sponsored by Gilead. © 2019 Elsevier España, S.L.U. All rights reserved.

Identifiants

pubmed: 32560767
pii: S0210-5705(20)30181-3
doi: 10.1016/S0210-5705(20)30181-3
pii:
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

1-7

Informations de copyright

Copyright © 2019 Elsevier España, S.L.U. Todos los derechos reservados.

Auteurs

José Castellote (J)

Servicio de Aparato Digestivo, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, España.; Universitat de Barcelona, Barcelona, España. Electronic address: jcastellote@bellvitgehospital.cat.

Francisco Gea (F)

Unidad de Sistema Digestivo, Hospital Universitario Ramón y Cajal, Madrid, España.

Luis Enrique Morano (LE)

Unidad de Patologías Infecciosas, Hospital Universitario Álvaro Cunqueiro, Vigo, Pontevedra, España.

Rosa M Morillas (RM)

Servicio de Aparato Digestivo, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; CIBEREHD, Instituto Carlos III, Madrid, España.

Juan Antonio Pineda (JA)

Unidad de Enfermedades Infecciosas y Microbiología, Hospital Nuestra Señora de Valme, Sevilla, España.

Mercedes Vergara (M)

CIBEREHD, Instituto Carlos III, Madrid, España; Unidad de Hepatología, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Barcelona, España.

María Buti (M)

Unidad de Hepatología, Hospital General Universitario Vall d'Hebron, Barcelona, España.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH